Weekly Investment Analysts’ Ratings Changes for Zymeworks (ZYME)

A number of research firms have changed their ratings and price targets for Zymeworks (NYSE: ZYME):

• 10/27/2025 – Zymeworks had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 10/24/2025 – Zymeworks is now covered by analysts at Wells Fargo & Company. They set an “equal weight” rating and a $15.00 price target on the stock.
• 10/16/2025 – Zymeworks had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $23.00. They now have an “overweight” rating on the stock.
• 10/14/2025 – Zymeworks was given a new $26.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
• 10/10/2025 – Zymeworks is now covered by analysts at B. Riley. They set a “buy” rating and a $30.00 price target on the stock.

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.